WO2013045600A1 - Novel peptide derivatives as antibiotics - Google Patents

Novel peptide derivatives as antibiotics Download PDF

Info

Publication number
WO2013045600A1
WO2013045600A1 PCT/EP2012/069166 EP2012069166W WO2013045600A1 WO 2013045600 A1 WO2013045600 A1 WO 2013045600A1 EP 2012069166 W EP2012069166 W EP 2012069166W WO 2013045600 A1 WO2013045600 A1 WO 2013045600A1
Authority
WO
WIPO (PCT)
Prior art keywords
xaa
compound
lysine
formula
hydroxylysine
Prior art date
Application number
PCT/EP2012/069166
Other languages
English (en)
French (fr)
Inventor
Maxime Gualtieri
Philippe Villain-Guillot
Alain Givaudan
Sylvie Pages
Original Assignee
Nosopharm
Institut National De La Recherche Agronomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nosopharm, Institut National De La Recherche Agronomique filed Critical Nosopharm
Priority to US14/342,446 priority Critical patent/US9260481B2/en
Priority to EP12778971.7A priority patent/EP2760881B1/en
Priority to ES12778971.7T priority patent/ES2657930T3/es
Priority to RU2014114996/04A priority patent/RU2014114996A/ru
Priority to CA2845735A priority patent/CA2845735A1/en
Priority to IN3010DEN2014 priority patent/IN2014DN03010A/en
Priority to JP2014532400A priority patent/JP6158188B2/ja
Priority to CN201280046610.4A priority patent/CN103827138B/zh
Publication of WO2013045600A1 publication Critical patent/WO2013045600A1/en
Priority to IL231664A priority patent/IL231664A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • Xaai is lysine; Xaa 2 and Xaa 3 are each 3-hydroxy-2,4- diaminobutanoic acid; Xaa 4 is glycine; Xaa 5 is ornithine; Xaa 6 is proline; Xaa 7 is histidine; Xaagis lysine or 5-hydroxylysine; Xaa 9 is 2,3-dehydroarginine; Xaagis lysine or 5-hydroxylysine; n is 4; and R is NH 2 .
  • FIG. 4 shows bactericidal effects of Odilomycin A on growing P. aeruginosa
  • the present invention comprises methods of treatment, suppression and/or prevention of bacterial infection comprising administration of extracts from Xenorhabdus nematophila strain CNCM 1-4530.
  • Xenorhabdus nematophila strain CNCM 1-4530 culture supernatant from this strain and cell extracts derived from this strain exhibit antibiotic activity against Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Klebsiella pneumonia, Klebsiella oxytoca, Acinetobacter baumannii, Enterobacter cloacae, Escherichia coli, Moraxella catarrhalis, Pseudomonas aeruginos and Stenotrophomonas maltophilia.
  • n 4.
  • one or more of Xaai, Xaa 2; Xaa 3 , Xaa , Xaa 5 , Xaa 6 , Xaa 7 , Xaa 8 , and Xaa ⁇ have the "D" configuration at the ⁇ -carbon of the amino acid residue.
  • the configuration at the hydroxyl groups in the amino acid side chains may be "R” or "S", and may be independent of the configurations of other hydroxyl groups in the compounds of formula (I).
  • one or more hydroxyl groups have the "R” configuration.
  • one or more hydroxyl groups have the "S” configuration.
  • each of the hydroxyl groups have the "R” configuration.
  • each of the hydroxyl groups have the "S” configuration.
  • compositions or methods may further comprise one or more additional antibacterial or antibiotic compounds in combination with a compound of formula (I) alone.
  • additional antibacterial or antibiotic compounds include, but are not limited to, daptomycin, oxacillin, piperacillin/tazobactam, ticaricillin/clavulanic acid, amoxicillin/clavulanic acid, erythromycin, cefepim, clindamycin, imipenem, gentamicin, ciprofloxacin, aztreonam, vancomycin, linezolid, rifampicin, kanamycin, ampicillin, tetracycline, and the like.
  • Another aspect of the present invention is a pharmaceutical composition comprising an effective amount of a compound of formula (I).
  • Xaai is lysine.
  • Xaa 5 is ornithine.
  • n 4.
  • the compound and/or composition is administered orally. In some embodiments, the compound and/or composition is administered subcutaneous ly. In some embodiments, the compound and/or composition is administered intravenously. In some embodiments, the compound and/or composition is administered intramuscularly. In some embodiments, the compound and/or composition is administered topically. In some embodiments, the compound and/or composition is administered parenterally.
  • Odilomycin A was tested for antimicrobial activity against a wide range of bacteria involved in nosocomial and animal infection. It owns a wide spectrum of antibacterial activity against Gram-positive and Gram-negative pathogens (Table 8). With respect to Gram-positive bacteria, the antibacterial activities of Odilomycin A are strong, with MICs inferior to 1 ⁇ g/mL against S. aureus, S. epidermidis, and B. subtilis strains, including against some multiresistant clinical isolates (Table 9). Weak or no antibacterial activity was observed against E. faecalis, E. faecium, S. pneumoniae, and S. pyogenes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/EP2012/069166 2011-09-28 2012-09-28 Novel peptide derivatives as antibiotics WO2013045600A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US14/342,446 US9260481B2 (en) 2011-09-28 2012-09-28 Peptide derivatives as antibiotics
EP12778971.7A EP2760881B1 (en) 2011-09-28 2012-09-28 Novel peptide derivatives as antibiotics
ES12778971.7T ES2657930T3 (es) 2011-09-28 2012-09-28 Nuevos derivados de péptidos como antibióticos
RU2014114996/04A RU2014114996A (ru) 2011-09-28 2012-09-28 Новые пептидные производные в качестве антибиотиков
CA2845735A CA2845735A1 (en) 2011-09-28 2012-09-28 Novel peptide derivatives as antibiotics
IN3010DEN2014 IN2014DN03010A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-09-28 2012-09-28
JP2014532400A JP6158188B2 (ja) 2011-09-28 2012-09-28 抗生物質としての新規なペプチド誘導体
CN201280046610.4A CN103827138B (zh) 2011-09-28 2012-09-28 新的作为抗生素的肽衍生物
IL231664A IL231664A0 (en) 2011-09-28 2014-03-23 Novel peptide histories as antibiotics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161540085P 2011-09-28 2011-09-28
EP11183034.5 2011-09-28
EP11183034 2011-09-28
US61/540,085 2011-09-28

Publications (1)

Publication Number Publication Date
WO2013045600A1 true WO2013045600A1 (en) 2013-04-04

Family

ID=47994311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/069166 WO2013045600A1 (en) 2011-09-28 2012-09-28 Novel peptide derivatives as antibiotics

Country Status (10)

Country Link
US (1) US9260481B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2760881B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6158188B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN103827138B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2845735A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2657930T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL231664A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN03010A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2014114996A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013045600A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046409A1 (en) * 2014-09-26 2016-03-31 Nosopharm Novel peptide derivatives and uses thereof
WO2024200838A1 (en) * 2023-03-31 2024-10-03 Nosopharm New odilorhabdins analogues as antibiotics against multi-resistant bacteria

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9800971B2 (en) 2015-03-17 2017-10-24 Knowles Electronics, Llc Acoustic apparatus with side port
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2207433A (en) * 1987-07-22 1989-02-01 Nat Res Dev Peptides
WO2002055545A1 (fr) * 2001-01-12 2002-07-18 Rhobio Pseudopeptides antimicrobiens
WO2010136532A1 (fr) * 2009-05-27 2010-12-02 Nosopharm Procédé pour augmenter la diversité des métabolites secondaires d'intérêt produits par des micro-organismes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2207433A (en) * 1987-07-22 1989-02-01 Nat Res Dev Peptides
WO2002055545A1 (fr) * 2001-01-12 2002-07-18 Rhobio Pseudopeptides antimicrobiens
WO2010136532A1 (fr) * 2009-05-27 2010-12-02 Nosopharm Procédé pour augmenter la diversité des métabolites secondaires d'intérêt produits par des micro-organismes

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1997, KRIEGER PUBLISHING COMPANY
BERDY J., J. ANTIBIOT., vol. 58, 2005, pages 1 - 26
BODANZKY ET AL.: "The Practice of Peptide Synthesis", 1994, SPRINGER-VERLAG
FORST & K NEALSON S: "Molecular biology of the symbiotic-pathogenic bacteria Xenorhabdus spp. and Photorhabdus spp", MICROBIOLOGICAL REVIEWS, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 60, no. 1, 1 March 1996 (1996-03-01), pages 21 - 43, XP002092718, ISSN: 0146-0749 *
GILBERT BANKER; CHRISTOPHER RHODES: "Modern Pharmaceutics", vol. 121, 2002, CRC PRESS
MARION D. ET AL., J. MAGN. RESON., vol. 85, 1989, pages 393 - 399
NOLDEN S ET AL: "Analysis of RegA, a pathway-specific regulator of the friulimicin biosynthesis in Actinoplanes friuliensis", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 140, no. 1-2, 10 March 2009 (2009-03-10), pages 99 - 106, XP025969909, ISSN: 0168-1656, [retrieved on 20090310], DOI: 10.1016/J.JBIOTEC.2008.12.013 *
PIOTTO M. ET AL., J. BIOMOL. NMR, vol. 2, 1992, pages 661 - 665
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOT, WILLIAMS & WILKINS
WUTHRICH K.: "NMR of Proteins and Nucleic Acids", 1986, JOHN WILEY & SONS

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046409A1 (en) * 2014-09-26 2016-03-31 Nosopharm Novel peptide derivatives and uses thereof
KR20170057400A (ko) * 2014-09-26 2017-05-24 노소팜 신규의 펩티드 유도체 및 그 용도
JP2017533890A (ja) * 2014-09-26 2017-11-16 ノソファルムNosopharm 新規ペプチド誘導体およびその使用
US10626144B2 (en) 2014-09-26 2020-04-21 Nosopharm Peptide derivatives and uses thereof
AU2015323713B2 (en) * 2014-09-26 2020-04-23 Nosopharm Novel peptide derivatives and uses thereof
JP2021100939A (ja) * 2014-09-26 2021-07-08 ノソファルムNosopharm 新規ペプチド誘導体およびその使用
JP7123559B2 (ja) 2014-09-26 2022-08-23 ノソファルム 新規ペプチド誘導体およびその使用
KR102522224B1 (ko) * 2014-09-26 2023-04-14 노소팜 신규의 펩티드 유도체 및 그 용도
WO2024200838A1 (en) * 2023-03-31 2024-10-03 Nosopharm New odilorhabdins analogues as antibiotics against multi-resistant bacteria

Also Published As

Publication number Publication date
EP2760881A1 (en) 2014-08-06
CA2845735A1 (en) 2013-04-04
IL231664A0 (en) 2014-05-28
ES2657930T3 (es) 2018-03-07
JP2014534173A (ja) 2014-12-18
IN2014DN03010A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-08
EP2760881B1 (en) 2017-11-01
US9260481B2 (en) 2016-02-16
US20150175659A1 (en) 2015-06-25
CN103827138A (zh) 2014-05-28
RU2014114996A (ru) 2015-11-10
JP6158188B2 (ja) 2017-07-05
CN103827138B (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
US9260481B2 (en) Peptide derivatives as antibiotics
US8299020B2 (en) Antimicrobial peptides and methods of their use
US11548916B2 (en) Anti-infective compound
Ning et al. Characterization of brevilaterins, multiple antimicrobial peptides simultaneously produced by Brevibacillus laterosporus S62-9, and their application in real food system
Hicks Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted Cα amino acids
EP2500022B1 (en) Antibacterial agent for drug-resistant bacteria and use of same
EP3111948A1 (en) New bicyclic lipopeptide, preparation and use as antimicrobial agent
Hashizume et al. Tripropeptin E, a new tripropeptin group antibiotic produced by Lysobacter sp. BMK333-48F3
Ji et al. Isolation and characterization of two novel antibacterial cyclic hexapeptides from Streptomyces alboflavus 313
Maffioli A Chemist's Survey of Different Antibiotic Classes
KR102158205B1 (ko) 항균 활성을 갖는 신규한 고리형 리포펩타이드계 화합물 및 이의 용도
WO2012085177A1 (en) Nemaucin, an antibiotic produced by entomopathogenic xenorhabdus cabanillasii
KR101344083B1 (ko) 폴리사이클릭 펩타이드 화합물을 포함하는 항균용 조성물 및 이의 생산방법
KR102167324B1 (ko) 백본-고리형 펩타이드와의 조합물
Sztaricskai et al. A new series of glycopeptide antibiotics incorporating a squaric acid moiety
Dubkara et al. Discovery of a potent ornithine-modified gramicidin S analogue against drug-resistant Staphylococcus aureus and Enterococcus faecalis with minimal red blood cell toxicity
Hashizume et al. A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3
Guan et al. A facile and selective derivatization approach on kynurenine-NH2 in daptomycin, leading to the discovery of hexakynomycin to combat multidrug-resistant Gram-positive pathogens especially daptomycin-resistant bacteria
Miller et al. Shipworm symbiosis ecology-guided discovery of Gram-negative selective antibiotic with activity against Acinetobacter
KR101987854B1 (ko) 고리형 헥사펩타이드계 화합물들 및 이의 용도
EP4132945A2 (en) Antibacterial lipopeptides, pharmaceutical composition and cosmetic composition comprising them, and uses thereof
Madu Exploring the Antimicrobial Potential of Small Molecule Produced by Streptomyces Davawensis
WO2024018398A1 (en) Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament
CN120623264A (zh) 一种抗菌肽lk-kjt-b01及其制备方法和应用
Ladell Isolation and characterization of antibiotics produced by the nematode symbiont Xenorhabdus szentirmaii

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12778971

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2845735

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14342446

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2012778971

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012778971

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 231664

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2014532400

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014114996

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014005710

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112014005710

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112014005710

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2436 DE 12/09/2017.

Ref document number: 112014005710

Country of ref document: BR